ReviewPharmacological research2015
Type 1 diabetes and gut microbiota: Friend or foe?
Review in Pharmacological research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Type 1 Diabetes Mellitus and Vitamin D.International journal of molecular sciences · 2025Review
- Microbiome Changes in Pregnancy Disorders.Antioxidants (Basel, Switzerland) · 2023Review
- Emerging trends and focus on the link between gut microbiota and type 1 diabetes: A bibliometric and visualization analysis.Frontiers in microbiology · 2023Article
- Host gene effects on gut microbiota in type 1 diabetes.Biochemical Society transactions · 2022Review
- The Role of Nutritional Factors in the Modulation of the Composition of the Gut Microbiota in People with Autoimmune Diabetes.Nutrients · 2022Review
- Evidence and possible mechanisms of probiotics in the management of type 1 diabetes mellitus.Journal of diabetes and metabolic disorders · 2022Review
- Gestational Diabetes Mellitus: The Crosslink among Inflammation, Nitroxidative Stress, Intestinal Microbiota and Alternative Therapies.Antioxidants (Basel, Switzerland) · 2022Review
- Ursolic acid regulates gut microbiota and corrects the imbalance of Th17/Treg cells in T1DM rats.PloS one · 2022Article
- Oral Administration of BacterialOxidative medicine and cellular longevity · 2022Article
- The Genetics of Diabetes: What We Can Learn fromInternational journal of molecular sciences · 2021Review
- Changes in the gut microbiota: a possible factor influencing peripheral blood immune indexes in non-obese diabetic mice.Antonie van Leeuwenhoek · 2021Article
- Gluten Free Diet for the Management of Non Celiac Diseases: The Two Sides of the Coin.Healthcare (Basel, Switzerland) · 2020Review
- Probiotics: Versatile Bioactive Components in Promoting Human Health.Medicina (Kaunas, Lithuania) · 2020Review
- Anthocyanins as Antidiabetic Agents-In Vitro and In Silico Approaches of Preventive and Therapeutic Effects.Molecules (Basel, Switzerland) · 2020Review
- Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
- Gastrointestinal Microbiota and Type 1 Diabetes Mellitus: The State of Art.Journal of clinical medicine · 2019Review
- Gut Microbiome Modulation Based on Probiotic Application for Anti-Obesity: A Review on Efficacy and Validation.Microorganisms · 2019Review
- Review
- Evaluation of different mucosal microbiota leads to gut microbiota-based prediction of type 1 diabetes in NOD mice.Scientific reports · 2018Article
- Retinoic Acid, Leaky Gut, and Autoimmune Diseases.Nutrients · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Type 1 diabetes is a T cell-mediated autoimmune disease. Environmental factors play an important role in the initiation of the disease in genetically predisposed individuals. With the improved control of infectious disease, the incidence of autoimmune diseases, particularly type 1 diabetes, has dramatically increased in developed countries. Increasing evidence suggests that gut microbiota are involved in the pathogenesis of type 1 diabetes. Here we focus on recent advances in this field and provide a rationale for novel therapeutic strategies targeting gut microbiota for the prevention of type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.